Research News

 

This resource on Type 1 Diabetes Research was created in partnership with JDRF through the JDRF – Beyond Type 1 Alliance.


 

Dedicated to Helping People With T1D: Dr. Gary Meininger on His Life and Career with Diabetes


We spoke with Dr. Meininger on his personal connection to T1D, his role at Vertex, and important work being done in clinical trials.MORE
vertex pharmaceuticals stem cell therapy for type 1 diabetes

Stem-Cell Therapy for Type 1 Diabetes Reduced Patient’s Insulin Needs by 91%


The early results of a clinical trial using stem-cell therapy to treat Type 1 diabetes reduced the patient’s insulin needs by 91%.MORE
teplizumab

FDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1D


The FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of Type 1 diabetes.MORE
teplizumab

FDA Advisory Committee Votes 10-7 To Recommend Approval of Teplizumab For Delay Of Type 1 Diabetes


Teplizumab is an investigational candidate proven to delay the onset of Type 1 diabetes. The FDA advisory committee reviews Provention Bio Inc.'s application.MORE

The PROTECT Study 


The PROTECT Study aims to understand how the investigational medicine, teplizumab, works in children and young adults who have recently been diagnosed with T1D, as well as assessing if there are any s...MORE

FDA Approves New Glucagon Option from Zealand Pharma


Available in June 2021, the FDA approved Zealand Pharma’s Zeagalogue, a new form of glucagon for people with insulin-dependent diabetes.MORE

JDRF Announces New Center of Excellence to Advance T1D Research


On February 23, 2021, JDRF announced the launch of the JDRF Center of Excellence in collaboration with the Harvard Stem Cell Institute in New England.MORE

Congress Renews Funding for Special Diabetes Program


On Dec 22, 2020, Congress renewed the Special Diabetes Program, providing $150 million annually in Type 1 diabetes research funding until 2023MORE

JDRF Launches Program to Advance Universal Screening for Type 1 Diabetes


T1Detect is a new screening initiative designed to make early detection of Type 1 diabetes easier and more accessible to a broad population. MORE

From Diagnosis Through Complications: Disparities in Diabetes Care


Recent research is confirming what many have experienced - that beginning at diagnosis, ethnic minorities in the US face more challenges navigating diabetes and care than their white counterparts. MORE

JDRF Announces Updated Strategy, Renewed Focus in Light of COVID-19


Amidst COVID-19, JDRF prioritizing work in their portfolio that they see as having the highest likelihood for cures and life changing advances for diabetes.MORE

Omnipod Closed Loop Technology to be Compatible with Both Abbott and Dexcom CGMs


Abbott and Dexcom announced formal partnerships with Insulet to be compatible as CGMs on the Omnipod Horizon Automated Insulin Delivery System. MORE

New Evidence Shows Vital Importance of Screening For T1D in Children


By screening for Type 1 diabetes in children, Bavaria was able to decrease rates of diabetic ketoacidosis at diagnosis.MORE

vTv Therapeutics Announces Positive Study Results of Potential First-in-Class Oral Adjunctive Therapy for T1D


On February 10, vTv Therapeutics announced positive study results from the second part of the Phase 2 Simplici-T1 Study of TTP399.MORE

JDRF CEO to Health Insurers: Cover New Technology


JDRF President & CEO Aaron Kowalski, Ph.D calls on insurers to cover FDA approved type 1 diabetes technologyMORE

Tandem’s Control-IQ Hybrid Closed Loop Approved by the FDA


The FDA announced the approval of the Control-IQ Hybrid Closed Loop System from Tandem Diabetes Care. The system sees the t:slim X2 insulin pump and Dexcom G6 continuous glucose monitor working togeth...MORE

Implanted PEC-01 Cells Capable of Producing Insulin According to New Data Presented from ViaCyte


ViaCyte presented preliminary data from their PEC-Direct trial, showing that PEC-01 cells are capable of producing insulin in patients with Type 1 diabetes.MORE

JDRF Launches Center of Excellence to Accelerate Cure for Type 1 Diabetes


On September 4, JDRF announced the launch of its Northern California Center of Excellence, dedicated to focused efforts on research and breakthroughs to cure Type 1 diabetes.MORE

Preventing Type 1 Diabetes: Results From TrialNet’s Landmark Teplizumab Trial


The immunotherapy drug teplizumab was shown to delay Type 1 diabetes diagnosis a median of 2 years in children and adults at high risk.MORE

Nonprofits Announce Groundbreaking Research Initiative


The Parker Institute, JDRF and The Leona M. and Harry B. Helmsley Charitable Trust announced a research initiative to study immunotherapy-induced diabetes. MORE

FDA Approves New Treatment for Diabetic Retinopathy


Regeneron Pharmaceuticals announced that the FDA has approved EYLEA (aflibercept) to treat all stages of diabetic retinopathy.MORE

 


To learn more about all the great T1D research being funded by JDRF, visit their research and impact page here.